The Cost of Evidence: Examining the FDA's Treatment of Critically-Needed Drugs from an Ex Ante Perspective
North Carolina Central University Science & Intellectual Property Law Review
Part of the Health Law and Policy Commons
Part of the Health Law and Policy Commons